Jiahui Hospital successfully discharged the first myeloma patient treated with CAR-T

The CAR-T therapy started in 2022 after a relapse from multiple myeloma.

Shanghai Jiahui International Hospital has discharged the first myeloma patient treated with CAR-T therapy, two weeks after infusion.

The patient, based in Shanghai, was first detected with multiple myeloma in 2008. Whilst he underwent treatments from chemotherapy to stem cell transplantations, he relapsed with extramedullary metastasis that led to multiple bone destruction in 2022.

His CAR-T treatment under Jiahui began in 2022. With the hospital’s international standard of healthcare, its accessibility, the availability of the equipment, and the readiness of the haematology team.

ALSO READ: Digital Implantology, Dentway’s route to minimal bleeding from implant surgery

Given the diagnosis of extramedullary multiple myeloma, including the exposure to over five lines of treatments and short remission, there was a risk of poor prognosis and urgency for more effective treatment. This makes CAR-T therapy as the best option.

“My entire treatment journey at Jiahui has been smooth throughout. I've had really good support from the medical team – from my doctors through to the nursing team. It's been a good experience,” the patient shared.

The CAR-T multidisciplinary treatment team in Jiahui, led by Dr. Vicky Lee, Director of the Jiahui International Cancer Center and Chief of Medical Oncology, has been exploring new concepts and technologies for treating blood cancer patients.